Smith & Nephew plc: Q3 2025 Trading Update Summary
Business Context and Reporting Period
This Form 6-K filing reports the third-quarter trading update for Smith & Nephew plc, a global medical technology company, for the period ended September 27, 2025. The company operates across three primary business units: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The update highlights progress under the company's "12-Point Plan" transformation strategy.
Key Financial Metrics
- Revenue: Q3 2025 revenue was $1,501 million, compared to $1,412 million in Q3 2024. This represents reported growth of 6.3% and underlying growth of 5.0%.
- Profit Margin: Full-year 2025 trading profit margin is expected to expand to between 19.0% and 20.0% (up from 18.1% in 2024).
- Cash Flow: Full-year free cash flow guidance has been raised to approximately $750 million, up from a previous guidance of more than $600 million.
- Capital Allocation: A $500 million share buyback program was completed on October 7, 2025.
- Currency Impact: Q3 reported growth included a 130 basis point tailwind from foreign exchange.
Material Changes vs. Prior Period
- Orthopaedics: Underlying revenue grew 4.1%. US Hip Implants showed strong growth (6.3%), offsetting a decline in US Knee Implants (-2.3%) due to portfolio rationalization. Robotics sales drove growth in Other Reconstruction (9.7% underlying).
- Sports Medicine & ENT: Underlying revenue grew 5.1%. Growth outside of China was 8.9%, as headwinds from Volume Based Procurement (VBP) in China began to abate. Sports Medicine Joint Repair grew 8.6% underlying.
- Advanced Wound Management: Underlying revenue grew 6.0%, led by double-digit growth (12.2%) in Advanced Wound Bioactives.
- Geography: US revenue grew 5.5% underlying. Emerging Markets grew 5.4% underlying, while Other Established Markets grew 3.9% underlying.
Guidance, Outlook, and Risks
- Full Year Outlook: Management expects full-year underlying revenue growth of around 5.0% (reported around 5.7%).
- Tariff Impact: The company anticipates a net negative impact of $15 to $20 million from tariffs in 2025, with potential compounding effects in 2026.
- Reimbursement Risks: A final update to Medicare reimbursement for skin substitutes (Advanced Wound Bioactives) is expected to be a headwind in 2026, potentially reducing Group trading profit margin by 25 to 50 basis points.
- China VBP: While VBP headwinds in Sports Medicine are easing, VBP processes for Arthroscopic Enabling Technologies and ENT are expected in 2026.
- Upcoming Events: Capital Markets Days are scheduled for December 8 and 11, 2025, to unveil a new post-12-Point Plan strategy. Full-year results will be released on March 2, 2026.
Investor Verification Checklist
- Verify the sustainability of US Hip Implant growth versus the continued decline in US Knee Implants due to portfolio rationalization.
- Monitor the actual impact of the new Medicare reimbursement rates for skin substitutes on 2026 margins.
- Assess the timeline and severity of upcoming Volume Based Procurement (VBP) implementations in China for Arthroscopic and ENT segments in 2026.
- Confirm the execution of the new mid-term strategy and financial goals to be presented at the December 2025 Capital Markets Days.
- Track the realization of the raised free cash flow guidance ($750 million) against working capital discipline in the fourth quarter.